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Background

Objectives
• To determine whether POE increases the likelihood of an altered immune
response, measured by the development of asthma, by eight years of age.

Methods
• A retrospective cohort design utilizing a comprehensive CERNER HealthFacts®
U.S. national database.
• CERNER HealthFacts® is a clinical database that captures de-identified,
longitudinal electronic health record data from 800 hospitals across the country.
• ICD-9-CM and ICD-10-CM diagnosis codes were used to identify infants born at
term with known prenatal opioid exposure or NOWS and were compared to
healthy control infants with no diagnoses at birth other than normal newborn
codes.
• Data analysis was conducted with IBM Statistical Package for Social Sciences
(version 26) and P values less than 0.05 were considered statistically significant.
• Descriptive statistics for frequencies and percentages were calculated. Pearson’s
Chi-Square test analysis was conducted to examine whether there was an
association between POE and asthma diagnosis as well as other variables of
interest.

Table 1. Characteristics of Study Participants (N = 3021)
n
Demographics
Gender
Female
Male
Unknown
Race/ethnicity
African American
Caucasian
Hispanic
Other
Insurance
Medicaid
Other commercial
Self-Pay
Not Specified
Community
Urban
Rural
Opioid Exposure
Exposed
Not Exposed
Asthma Diagnosis
Yes
No

Percentage of Patients with Asthma Diagnosis with POE Compared to Control
%

1420 47
1531 50.7
70
2.3
468 15.5
1843 61
165 5.5
545
18

Percentage with Asthma Diagnosis

• An estimated 1 in 3 women of reproductive age filled an opioid prescription every
year from 2008 to 2012 in the United States.
• The number of women admitted for L&D with Opioid Use Disorder (OUD)
quadrupled from 1999 to 2014.
• Neonatal Abstinence Syndrome (NAS) diagnoses increased in the United States
from 3.4 to 5.8 per 100 hospital visits between 2009 and 2012, totaling over
21,000 infants affected during these three years.
• Neonatal Opioid Withdrawal Syndrome (NOWS), a specific form of NAS,
presents with unique clinical features including dysfunction in the following four
domains: state control and attention, motor and tone control, sensory integration,
and autonomic functioning.
• Recent studies suggest that children diagnosed with NOWS are more likely to
have lower intelligence quotient scores, educational disabilities/deficits, and
visual disorders.
• Children diagnosed with NOWS are more likely to require re-hospitalization or
frequent healthcare follow up. Common reasons for re-hospitalization include
respiratory disease, infections, and injuries.
• Preclinical models have revealed the presence of pro-inflammatory markers in the
peripheral circulation and brain following prenatal opioid exposure (POE), which
may in turn alter the developing immune system.
• Asthma is a heterogeneic chronic inflammatory disease that varies in the type and
intensity of airway inflammation.
• The specific underlying inflammatory mechanisms involved in the progression of
asthma remain unknown.

Results

Results

Patients With Asthma Diagnosis
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Prenatal Opioid
Exposure

Patient Group

1265 41.9
619 20.5
106 3.5
1031 34.1
2795 92.5
226 7.5
1523 50.4
1498 49.6
172 5.7
2849 94.3

Table 1 shows the characteristics of the study participants, in which a total of 3,021
records from 2000 to 2016 were reviewed. The chart of each patient was reviewed
until 8 years of age. A total of 50.4% of patients had POE and 49.6% had no known
exposure.
• There was no difference in the percentage of patients that were male compared to
female.
• Sixty-one percent of patients were identified as Caucasian, 15.5% as African
American and 5.5% as Hispanic.
• The majority of patients had Medicaid insurance and resided in urban locations.

Of infants diagnosed with asthma (n = 172),
66.3% were prenatally exposed to opioids
while 33.7% were not exposed.

Figure 1: Asthma diagnosis differed significantly by group (X2 [1, n = 3,021] =
18.36, p<0.001). The odds of an infant developing asthma were two times higher
for the group exposed to opioids prenatally (OR 2.1, 95% CI: 1.4-3.0) and this
was statistically significant (p<0.0001). After controlling for race, gender,
demographics and payment type, we observed that infants with POE had twice the
odds of diagnosis of asthma compared to infants who did not have POE.

Conclusions
• Our findings show an increased incidence of asthma in children prenatally
exposed to opioids. This is consistent with previous investigations of the
association between maternal drug use and risk of childhood asthma.
• This association highlights the importance of close follow up care within this
patient population.
• A major strength of this study was the ability to query a national database which
covers a wide area and a vast patient population. Therefore, we would expect the
results from this study to be applicable to other areas in the United States.
• Limitations are present in this study as we had to assume the codes used were
accurate and truly represented the patient. The diagnostic codes used to identify
infant with prenatal opioid exposure were not exclusive to opioids only (such as
Drug Withdrawal Syndrome in Newborn) so there may be some infants included
in the study that had prenatal exposure to a drug other than an opioid.
Additionally, there are confounding characteristics, such as smoking in the
household, that we are unable to account for.
• A future aim is to complete a longitudinal, prospective, multisite study to
address the weaknesses we have identified.
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